AvePoint (AVPT) CEO Jiang granted options and performance-based RSUs

Q: How do the new stock options for AvePoint (AVPT) CEO Tianyi Jiang vest?

The 252,609 stock options vest over time. 25% of the underlying shares vest on March 16, 2027, with the remaining options vesting in 12 equal quarterly installments thereafter, contingent on Jiang’s continued service with AvePoint at each vesting date.

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

AvePoint, Inc. director and Chief Executive Officer Tianyi Jiang reported equity awards that increase his direct holdings in the company. He received stock options for 252,609 shares of common stock at an exercise price of $10.52 per share, vesting 25% on March 16, 2027 and the remainder in 12 equal quarterly installments, subject to continued service.

He also acquired 147,338 shares of common stock at no cost, representing a mix of restricted stock units and performance-based RSUs under the 2021 Equity Incentive Plan. These performance-based RSUs depend on annual recurring revenue growth from 2026–2028 and 2028 GAAP profitability, with potential payouts ranging from 50% to 200% of the granted value. Following these grants, his reported direct holdings include 2,299,627 shares of common stock (including RSUs) and 2,756,670 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Jiang Tianyi

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	252,609	$10.52	$2.66M
Grant/Award	Common Stock	147,338	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 2,756,670 shares (Direct); Common Stock — 2,299,627 shares (Direct)

Footnotes (1)

This security represents the Issuer's common stock as well as restricted stock units (each, an "RSU") granted to the Reporting Person under the Issuer's 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. Represents performance-based RSUs ("PRSUs") based upon two metrics: Annual recurring revenue compounded annual growth rate for the years 2026-2028 (70% weighted) and FY 2028 GAAP profitability (30% weighted). Actual payouts may represent 50% to 200% of granted value. These PRSUs will fully vest upon certification of the actual payouts by the Issuer's Compensation Committee after the performance period ends. Includes non-RSU common stock as well as aggregate vested and unvested RSUs held by the Reporting Person subject to the vesting schedules previously reported on Table I of Form 4s filed with the Securities and Exchange Commission on September 3, 2021, March 22, 2022, March 23, 2023, March 7, 2024, and March 18, 2025. This security represents options to purchase the Issuer's common stock granted to the reporting person under the Issuer's 2021 Equity Incentive Plan. Each option represents the contingent right to receive, upon exercise of the option, one share of the Issuer's common stock. 25% of the shares underlying these options will vest on March 16, 2027, and the remaining options vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/18/2026 - 08:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jiang Tianyi

(Last)

(First)

(Middle)

C/O AVEPOINT, INC.

525 WASHINGTON BOULEVARD, SUITE 1400

(Street)

JERSEY CITY

NEW JERSEY

07310

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AvePoint, Inc. [ AVPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	03/16/2026		A		147,338⁽²⁾	A	$0	2,299,627⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)⁽⁴⁾	$10.52	03/16/2026		A		252,609		03/16/2027⁽⁵⁾	03/16/2036	Common Stock	252,609	$10.52	2,756,670	D

Explanation of Responses:

1. This security represents the Issuer's common stock as well as restricted stock units (each, an "RSU") granted to the Reporting Person under the Issuer's 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

2. Represents performance-based RSUs ("PRSUs") based upon two metrics: Annual recurring revenue compounded annual growth rate for the years 2026-2028 (70% weighted) and FY 2028 GAAP profitability (30% weighted). Actual payouts may represent 50% to 200% of granted value. These PRSUs will fully vest upon certification of the actual payouts by the Issuer's Compensation Committee after the performance period ends.

3. Includes non-RSU common stock as well as aggregate vested and unvested RSUs held by the Reporting Person subject to the vesting schedules previously reported on Table I of Form 4s filed with the Securities and Exchange Commission on September 3, 2021, March 22, 2022, March 23, 2023, March 7, 2024, and March 18, 2025.

4. This security represents options to purchase the Issuer's common stock granted to the reporting person under the Issuer's 2021 Equity Incentive Plan. Each option represents the contingent right to receive, upon exercise of the option, one share of the Issuer's common stock.

5. 25% of the shares underlying these options will vest on March 16, 2027, and the remaining options vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ Brian Michael Brown, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did AvePoint (AVPT) CEO Tianyi Jiang receive in this Form 4?

Tianyi Jiang received stock options for 252,609 shares at an exercise price of $10.52 and 147,338 shares of common stock via RSU and PRSU grants under AvePoint’s 2021 Equity Incentive Plan, all classified as grant or award acquisitions.

How do the new stock options for AvePoint (AVPT) CEO Tianyi Jiang vest?

The 252,609 stock options vest over time. 25% of the underlying shares vest on March 16, 2027, with the remaining options vesting in 12 equal quarterly installments thereafter, contingent on Jiang’s continued service with AvePoint at each vesting date.

What performance conditions apply to AvePoint (AVPT) CEO Tianyi Jiang’s performance-based RSUs?

The performance-based RSUs are tied to two metrics for 2026–2028: annual recurring revenue compounded annual growth rate (70% weight) and fiscal 2028 GAAP profitability (30% weight). Actual payouts may range from 50% to 200% of the granted value, based on these results.

When will AvePoint (AVPT) CEO Tianyi Jiang’s PRSUs fully vest?

The performance-based RSUs will fully vest after the performance period ends and AvePoint’s Compensation Committee certifies the actual payout levels. Vesting therefore depends on committee certification following assessment of revenue growth and GAAP profitability metrics through 2028, as described in the grant terms.

How many AvePoint (AVPT) common shares does CEO Tianyi Jiang hold after these grants?

After these awards, Jiang directly holds 2,299,627 shares of common stock, including both non-RSU shares and aggregate vested and unvested RSUs. This figure reflects multiple prior grants reported in earlier Form 4 filings under AvePoint’s 2021 Equity Incentive Plan.

What is Tianyi Jiang’s total AvePoint (AVPT) stock option position after this Form 4?

Following the new grant, Jiang holds 2,756,670 stock options to purchase AvePoint common stock. Each option represents the right to receive one share upon exercise, subject to the vesting schedule and the $10.52 exercise price for this particular award.